Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010 - 2020

by Selleckchem | Aug 14 2023

Alzheimer's disease (AD) is the most common form of dementia. There is currently no cure, and the available pharmacological treatment focuses on treating the symptoms. This study aimed to analyze the pharmacological treatments for AD protected in the US Patent Office. The Matheo Patent software was used to search for patents granted in the 2010-2020 period in the USPTO database. The search strategy «Alzheimer» was used in title and abstract and the International Patent Classification (IPC) codes A61P* and A61K*. The selected patents were divided into six categories according to therapeutic target. Complementary information from scientific databases was used to determine the stage of investigation and efficacy of the patented molecules. In the analyzed period, 58 patents were granted: 10 directed to Aβ peptide metabolism and deposition, three to tau, seven to inflammation, nine to cholinergic, two to glutamatergic and 27 to other targets. More than 80.0% belong to holders from the USA, France, and Japan. The molecules Elenbecestat and LY3202626 decreased the burden of Aβ plaques without significant cognitive improvement, Donanemab is in Phase 3 clinical trial, and the FDA has designated it Breakthrough Therapy. CPC-201 and PXT864 demonstrated, in Phase 2, good tolerability and improvement of AD symptoms. Most of the inventions are focused on treating the earliest phase of AD. The most advanced treatments in their research are those focused on treating Aβ accumulation. More studies are needed to prove the efficacy of the patented molecules.

Comments:

The study analyzed pharmacological treatments for Alzheimer's disease (AD) that are protected in the US Patent Office. The researchers used the Matheo Patent software to search for patents granted between 2010 and 2020 in the USPTO database. The search strategy focused on the term "Alzheimer" in the title and abstract, along with International Patent Classification (IPC) codes A61P* and A61K*.

Based on the search criteria, 58 patents were granted during the analyzed period. These patents were divided into six categories based on their therapeutic target. The categories included Aβ peptide metabolism and deposition (10 patents), tau (3 patents), inflammation (7 patents), cholinergic (9 patents), glutamatergic (2 patents), and other targets (27 patents).

The majority of patents (more than 80.0%) belonged to holders from the USA, France, and Japan. The study also utilized complementary information from scientific databases to determine the stage of investigation and efficacy of the patented molecules.

Among the analyzed patents, two molecules called Elenbecestat and LY3202626 were found to decrease the burden of Aβ plaques without significant cognitive improvement. Donanemab, on the other hand, is currently in Phase 3 clinical trial and has been designated as a Breakthrough Therapy by the FDA. Additionally, CPC-201 and PXT864 demonstrated good tolerability and improvement of AD symptoms in Phase 2 trials.

Most of the inventions focused on treating the earliest phase of AD, and the most advanced treatments in terms of research targeted Aβ accumulation. However, the study suggests that further research is necessary to establish the efficacy of the patented molecules.

It's important to note that the information provided is based on the study you mentioned, and the findings and status of the mentioned molecules may have evolved since the study was conducted. It's always recommended to consult up-to-date scientific literature and clinical trial databases for the latest information on Alzheimer's disease treatments.